ABSTRACT
Objectives The aim of the study was to characterize the circulating immunome of patients with EoE before and after proton pump inhibitor (PPI) treatment in order to identify potential non-invasive biomarkers of treatment response.
Methods PBMCs from 19 healthy controls and 24 EoE patients were studied using a 39-plex spectral cytometry panel. The plasmacytoid dendritic cell (pDC) population was differentially characterized by spectral cytometry analysis of immunofluorescence assays in esophageal biopsies from 7 healthy controls and 13 EoE patients.
Results Interestingly, EoE patients at baseline had lower levels of circulating pDC compared with controls. Before treatment, patients with EoE who responded to PPI therapy had higher levels of circulating pDC and classical monocytes, compared with non-responders. Moreover, following PPI therapy pDC levels were increased in all EoE patients, while normal levels were only restored in PPI-responding patients. Finally, circulating pDC levels inversely correlated with peak eosinophil count and pDC count in esophageal biopsies. The number of tissue pDCs significantly increased during active EoE, being even higher in non-responder patients when compared to responder patients pre-PPI. pDC levels decreased after PPI intake, being further restored almost to control levels in responder patients post-PPI.
Conclusions We hereby describe a unique immune fingerprint of EoE patients at diagnosis. Moreover, circulating pDC may be also used as a novel non-invasive biomarker to predict subsequent response to PPI treatment.
WHAT IS KNOWN
Eosinophilic esophagitis (EoE) is a Th2 type immune disorder with increased prevalence in the last years.
Proton pump inhibitor (PPI) treatment is the preferred first-line therapy for EoE, which leads to clinical and pathological reversion in about half of the cases. Non-responding patients require other therapeutic options.
Currently, an endoscopy with esophageal biopsies is required for EoE diagnosis and to monitor response to treatment. Therefore, the discovery of non-invasive biomarkers is of utmost importance for treatment monitoring.
To date only peripheral eosinophil and Th2 profiles have been studied in EoE.
WHAT IS NEW HERE
At diagnosis EoE patients have a specific circulating immune signature.
PPI-responding and non-responding EoE patients have different immune fingerprints at baseline.
Immune characterization of EoE patients at diagnosis and after PPI treatment unveiled differential levels of circulating plasmacytoid dendritic cells (pDCs) depending on their inflammatory state and response to PPI treatment. Those levels are related with the number of pDCs infiltrated in the esophageal tissue.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PM and CS are supported by grants PI17/0008 and ISCIII/Proteored 2019 of Instituto de Salud Carlos III (ISCIII, Spain) and co/funded by Fondo Europeo de Desarrollo Regional (FEDER). CS is also funded by Asociacion Espanola de Gastroenterologia (AEG) 2019 grant. DB is funded through the Spanish Ministry of Science [PID2019/ 104218RB/I00], Programa Estrategico Instituto de Biologia y Genetica Molecular (IBGM Junta de Castilla y Leon. Ref. CCVC8485) and the European Commission/ NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform. LU/T is recipient of an INVESTIGO contract from Comunidad de Madrid (09/ PIN1/00015.6/2022) partly funded by the European Social Fund, NextGenerationEU, and Recovery, Transformation and Resilience Plan. CR/R is recipient of an INVESTIGO contract from Ministry of Labour and Social Economy, the national public employment service (SEPE) (INVESTIGO Exp. 2022 C23.I01.P03. S0020 0000031) partly funded by the European Social Fund, NextGenerationEU, and Recovery, Transformation and Resilience Plan.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Hospital Universitario de la Princesa gave ethical approval for this work (PI17/0008, registry number 3107, 8 June 2017)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
ABBREVIATIONS
- EoE
- Eosinophilic esophagitis
- EoEHSS
- Eosinophilic Esophagitis Histologic Scoring System
- EREFS
- EoE endoscopic reference score
- GERD
- Gastro-esophageal reflux disease
- LN
- Lymph node
- LogFC
- Log2 Fold Change
- NR
- Non-responder
- PBMCs
- Peripheral blood mononuclear cells
- pDC
- Plasmacytoid dendritic cells
- PPI
- Proton Pump Inhibitors
- R
- Responder
- Th2
- T helper 2 cells
- UMAP
- Uniform Manifold Approximation and Projection
